In today’s always-on world, people are more digitally-connected than ever before – yet less connected to one another in meaningful ways. That’s why Murad®, the pioneering clinical skincare brand, is launching the EyesUp Campaign, a new initiative designed to educate people about the danger of digital-only relationships and the power of real-world human connection. Through the campaign, Murad is encouraging people around the world to go “EyesUp” and connect with one another in real life.
Renowned as the “Father of Internal Skincare,” Dr. Murad’s groundbreaking work and research over the past decade has centered on helping people cope with Cultural Stress™, or the stress of modern living. The hallmarks of Cultural Stress include digital dependency, the inability to disconnect from work, and lowered self-esteem due to increased social expectations.
To view the multimedia release go to:
https://www.multivu.com/players/English/7833456-murad-skincare-eyesup-campaign/
See America, Allergan’s initiative to fight against preventable blindness in the United States, today unveiled a powerful video featuring award-winning actor and hip-hop artist Common, that urges Americans to “stand in the way of darkness”.
The video harnesses Common’s striking spoken word ability, calling on Americans to fight against vision loss and prioritize their vision. Common highlights the 61 million Americans at-risk of severe vision loss, and challenges us all to imagine a life without sight.
“I'm proud to join Allergan in the fight against preventable blindness,” said Common. “Sight is something that far too many of us take for granted. I hope our message resonates with people across the country, no matter what age or background.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8057551-common-joins-allergan-see-america-against-preventable-blindness/
Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE.
To view the multimedia release go to:
https://www.multivu.com/players/English/8056151-csl-behring-subcutaneous-c1-esterase-inhibitor-hae-patients/
Living with type 1 diabetes comes with many unique challenges in all stages of life. For parents of children with the condition, financial, medical and emotional worries can be overwhelming. To help support people with diabetes and those who love them, Lilly Diabetes today announced it will donate $94,000 to the American Diabetes Association (Association) Campership program and $100,000 to the Diabetes Scholars Foundation (Foundation).
To view the multimedia release go to:
http://www.multivu.com/players/English/8004851-lilly-diabetes-scholarship-donations/
In new research from U by Kotex®, three in five women surveyed stated it is more difficult to exercise during their period and the majority reported opting for less challenging workouts.
U by Kotex® is hoping to rid barriers with the launch of its latest innovation – U by Kotex® FITNESS. To meet the needs of people experiencing a period, the brand is introducing three new product offerings, including:
• NEW U by Kotex Fitness Tampons with a plastic FITPAK* so you can protect your protection. Durable, compact, and discreet, FITPAK* is designed to keep your tampons ready for use, wherever you stash them.
• NEW U by Kotex Fitness Liners have DualFlex Zones* that move with you to keep protection where you need it.
• NEW U by Kotex Fitness Ultra Thin Pads are shaped to fit and flex with your body, to stay in place so you don’t have to.
To view the multimedia release go to:
https://www.multivu.com/players/English/8073651-u-by-kotex-findyourfitness/
Nearly 7,000 women from around the world took to New York’s Central Park on Sunday, April 30, to participate in the 14th Annual SHAPE Women's Half-Marathon. The race, presented by SHAPE magazine in partnership with the New York Road Runners (NYRR), is one of the largest women’s-only half-marathons in the country.
“It’s always inspiring to see so many beautiful and strong women pounding the pavement in Central Park,” says SHAPE Editor-in-Chief Elizabeth Goodman Artis. “We’re thrilled to be a part of this empowering event.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8091051-shape-womens-half-marathon-2017/
Varian Medical Systems (NYSE: VAR) today is introducing the Halcyon™ system, an entirely new device for cancer treatment. Engineered to revolutionize clinical workflow, Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT). This new treatment system is designed to expand the availability of high quality cancer care globally and help save the lives of millions more cancer patients.
“The global cancer challenge is enormous,” said Kolleen Kennedy, president of Varian's Oncology Systems business. “It is expected that there will be 24.6 million cancer cases diagnosed annually by 2030, and there is an acute shortage of equipment and trained clinicians. With the innovations in this new technology platform, the system will deliver high quality Halcyon treatments that empower clinicians to care for many more patients. At Varian we are very excited with the introduction of Halcyon to be taking another big step toward advancing cost-effective cancer care worldwide.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8065951-varian-medical-systems-halcyon-cancer-treatment/
Allied Universal, a leading facility services company and the largest security force in North America, together with John Jay College and the Metropolitan Healthcare Security Directors Association (MHSDA), will host a “Plan to Live” seminar to educate healthcare providers on best practices to handle an active shooter situation and other threats. The free seminar will be held Tues., May 16, from 9 a.m. to 1:30 p.m. in the college’s Moot Court at 899 10th Avenue, New York City.
“Active shooters are not the only risks that healthcare facilities face,” said Kevin Francis, Business Development Specialist, Allied Universal. “Healthcare facilities may encounter aggressive assailants, bomb threats, and terrorist attacks. Our seminar provides tips and information from leading experts to help them prepare for, survive and recover from an attack.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7883351-allied-universal-john-jay-active-shooter-seminar/
Capatriti Olive Oil teams up with celebrity chef and owner of “Streets” restaurant in Brooklyn, NY, Roblé Ali, to create viral videos featuring delicious spring and summer themed dishes to benefit celebrity-backed NYC charity organization, God’s Love We Deliver. Consumers can join in on the effort to donate funds toward the amazingly honest and sincere mission of God’s Love We Deliver to help those with severe and chronic illnesses through nutritious meals. Share Capatriti’s Honest Olive Oil campaign videos featuring Chef Roblé on Facebook, Instagram or Twitter and tag @CapatritiOliveOil and #HonestOliveOil. For every share, repost or retweet on social media, Capatriti will donate $1 to God's Love We Deliver, up to $5,000.
To view the multimedia release go to:
https://www.multivu.com/players/English/8077251-capatriti-gourmet-factory-honest-olive-oil-campaign/
Hunova, the first robotic gym for the rehabilitation and functional motor sense evaluation of lower limbs and trunk, has been officially launched in Genoa, Italy. The first 30 robots will be available from June in Europe and the USA. The technology was developed and patented at the IIT laboratories and has been launched on the market thanks to a 10 million euro investment from entrepreneur Sergio Dompè.
Hunova is a programmable robotic medical device that allows professionals in the geriatrics, neurology and sport rehabilitation field to cure and predict many neurological and orthopedic conditions. There are two main competitive advantages of this technology: Hunova is able to collect a significant amount of data on biomechanics, constantly monitoring the patient’s progress. Secondly, it provides direct support to the patient through a guiding robotic system, offering a wide range of rehabilitation protocols in the form of video games. It consists of two electromechanical platforms equipped with sensors, characterized by two degrees of freedom (feet and seat level). The device integrates the force sensors to adjust the interaction with the patient and a wireless sensor, which is placed on the patient’s trunk, allowing the physiotherapist to check the movement of the torso.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8108951-iit-movendo-launch-robot-hunova/
We get it, filters are the perfect skin fix for all things social, but what about your real-life beauty routine? Ditch the filters and take the #peelchallenge with Exuviance Performance Peel AP25 to reveal your own radiant, glowing complexion.
Experience the benefits of this high performance 25% blend of Alpha and Poly Hydroxy Acids including Glycolic Acid, Mandelic Acid, and Gluconolactone. Exuviance Performance Peel AP25, developed by the original patent holders of the Glycolic Acid peel, exfoliates dead, dull surface layers, and encourages cell renewal for fresher, healthier-looking skin.
To view the multimedia release go to:
https://www.multivu.com/players/English/7965751-exuviance-performance-peelchallenge-ap25/
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/
